Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014502 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by ImmunoGenesis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 5
- Study locations
NCT06014502 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by ImmunoGenesis. The registered enrollment target is 105 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (52% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06014502, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by ImmunoGenesis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in select cancer types.
Conditions Studied
Interventions
- DRUG IMGS-001
Study Locations (5)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Sarcoma Oncology Center - Santa Monica
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06014502
The ClinicalTrials.gov registry entry for NCT06014502 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (52% lower). The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMGS-001 is the first listed.
NCT06014502 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06014502 about?
NCT06014502 is a clinical study titled "Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors". The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their ...
What is the current status of trial NCT06014502?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2023-09-07. Estimated completion is 2027-12.
What conditions does trial NCT06014502 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06014502?
The interventions under investigation include: IMGS-001 (DRUG).
Who is sponsoring clinical trial NCT06014502?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014502 being conducted?
This trial has 5 study locations across Arizona, California, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.